Introduction
Estrogens are carcinogenic in humans and rodents (1, 2) , but the mechanisms by which these hormones induce cancer are not fully elucidated (3) . Epigenetic mechanisms of estrogens, related to stimulation of cell proliferation, mediated through the estrogen receptor are not sufficient to explain the carcinogenic activity of estrogens in vivo and in vitro (4) . Accumulating evidence has suggested that another mechanism related to genetic alterations is involved in the initiation of estrogen-induced carcinogenesis (4, 5) . The mutagenic mechanism of estrogens, in conjunction with the epigenetic mechanism, may contribute to hormonal carcinogenesis.
Endogenous estrogens are implicated as a possible etiological factor in the causation of certain types of human cancers such as breast, endometrium, ovary, prostate and, possibly, brain cancers (6) . Catechol estrogens, particularly the 4-hydroxy metabolites of 17β-estradiol (E 2 ) and estrone (E 1 ), are possible critical intermediates in estrogen-induced cancer. Exposure for 6-10 months by implantation of 4-hydroxyestradiol (4-OHE 2 ) or 4-hydroxyestrone (4-OHE 1 ) induces renal carcinomas in male Syrian hamsters (7, 8) .
Administration of E 2 , 2-OHE 2 or 4-OHE 2 for 12-18 months also induces uterine adenocarcinomas in mice, and the carcinogenic abilities of these estrogens are ranked as follows: 4-OHE 2 > 2-OHE 2 > E 2 (9) . The oxidative metabolites of 2-or 4-OHE 1 (E 2 ), i.e. E 1 (E 2 )-2,3 or 3,4-quinones, covalently bind to calf thymus DNA and form DNA adducts (10) . Cavalieri et al. (11) found that intramammillary injection of 4-OHE 2 or E 2 -3,4-quinone results in DNA adducts in mammary glands of female Sprague-Dawley rats. Treatment of Syrian hamster embryo (SHE) fibroblasts, which have endogenous oxidative and peroxidative metabolizing enzymes, with 2-OHE 2 or 4-OHE 2 induces DNA adducts, in parallel with the induction of cellular transformation (12) . These results suggest that oxidative metabolites of catechol estrogens play an important role in the initiation of endogenous estrogen-induced cancers.
Chemically induced DNA damage that may initiate various cancers can be examined by detection of DNA adducts through covalent modification of the DNA. Liehr et al. (13, 14) demonstrated the presence of covalent DNA adducts in the premalignant lesion in the kidneys of male Syrian hamsters treated with E 2 or diethylstilbestrol (DES) by using a 32 P-postlabeling assay. Adduct formation in the kidney DNA is detected at 1-3 months but not at 2 weeks after the beginning of treatment. DNA adducts are also detected in kidney, liver and other organs of hamsters 4 h after treatment with an i.p. injection of a single dose of DES (15) . Although these data support a genotoxic mechanism of E 2 or DES, the correlation between DNA adduct formation and the initiation of the estrogen-induced carcinogenesis still remains to be clarified.
We have used SHE fibroblast cell cultures as a model system to study the ability of estrogens to transform cells directly (4) . An advantage of the SHE cell model for studies of carcinogenesis is that cellular transformation and genetic effects can be measured in the same target cells (16) . SHE cells do not express measurable levels of estrogen receptor, and estrogen treatment is not mitogenic to the cells (4) . Thus, estrogenic stimulation of cell proliferation can be excluded as the mechanism of action for cellular transformation in this in vitro assay. The cells do, however, have the ability to metabolize estrogens (4) . We have shown that treatment of SHE cells with E 2 , E 1 or four of their catechol estrogens induces cellular transformation. The transforming abilities of the estrogens vary with the following rank order: 4-OHE 1 Ͼ 2-hydroxyestrone (2-OHE 1 ) Ͼ 4-OHE 2 Ͼ 2-OHE 2 Ն E 2 , E 1 (17) . In the present study, to examine a direct involvement of catechol estrogens in the initiation of estrogen-induced cell transformation, we studied the abilities of these estrogens to induce DNA adducts in SHE cells by using a 32 P-post-labeling assay, and compared these findings with the transforming abilities.
Materials and methods
Cells and chemicals SHE cell cultures were established from 13-day gestation Syrian hamster fetuses and grown as described previously (16) . E 2 , 2-OHE 2 , 4-OHE 2 , E 1 , 2-OHE 1 and 4-OHE 1 were purchased from Sigma (St Louis, MO). E 1 and E 2 were dissolved with dimethyl sulfoxide (DMSO; Sigma) at 10 mg/ml. Their catechol estrogens and benzo[a]pyrene (B[a]P; Sigma) were dissolved with DMSO at 3 and 1 mg/ml, respectively. These solutions were diluted with complete medium to the final concentrations. L-Ascorbic acid phosphate magnesium salt n-hydrate (L-ascorbic acid; Wako Pure Chemical, Osaka, Japan) was dissolved with complete medium and filter-sterilized.
Cytotoxicity
The cytotoxicity of test estrogens on SHE cells was determined from the colony-forming efficiency (CFE) of cells treated with the estrogens. Cells (5ϫ10 5 ) were plated into 75-cm 2 flasks (Costar, Cambridge, MA), incubated for 2 days, and treated with various test estrogens at 1-10 µg/ml (~3.5-37 µM) for 6 h. Control cultures were incubated with medium containing 0.33% DMSO (DMSO medium); this concentration did not affect the CFE as compared with untreated cells. After cells were trypsinized, 2000 cells were replated, in triplicate, onto 100-mm dishes (Costar) and incubated for 7 days for colony formation. Cells were fixed with absolute methanol and stained with a 10% aqueous Giemsa solution. The number of surviving colonies with Ͼ50 cells was then counted and the percent cell survival expressed as the number of colonies in the treated dishes divided by the number in control dishes ϫ100. Statistical analysis was performed by Student's t-test.
Isolation of DNA and 32 P-post-labeling Cells (5ϫ10 5 ) were plated into 75-cm 2 flasks, incubated for 2 days and treated with test estrogens at varying concentrations for 1-6 h. Exposure of cells to B[a]P with the same treatment regimen was used as a positive control. Control cultures were incubated with DMSO medium, which did not affect DNA adduct formation as compared with untreated cultures. DNA from the treated cells was isolated as described previously (12) . DNA adducts were analyzed by the nuclease P1 enhancement version of the 32 P-post-labeling assay (12, 18) . Briefly, 20 µg of isolated DNA was digested to deoxyribonucleoside 3Ј-monophosphates with 6 U of micrococcal nuclease (Worthington, Freehold, NJ) and 0.06 U of spleen phosphodiesterase (Worthington). The digest of DNA (10 µg) was then incubated with 4 mg nuclease P1 per ml (Sigma) for 1 h at 37°C and subsequently 32 P-labeled with a mixture of 5 U of T4 polynucleotide kinase (USB, Cleveland, OH) and 21 pmol of [γ-32 P]ATP (259 TBq/mmol, ICN, Irvine, CA) for 1 h at 37°C. Unreacted [γ-32 P]ATP was digested with 3.3 U/ml apyrase for 45 min at 37°C. Labeled DNA adducts were mapped by chromatography on polyethyleneimine (PEI) cellulose sheets (Polygram CEL 300 PEI, Machery-Nagel, Düren, Germany) and developed with 2.3 M sodium phosphate buffer (pH 6.0) (D1). Adducts remaining at the original spot were contact-transferred to a new PEI cellulose sheet and developed in 3.8 M lithium formate/6.8 M urea (pH 3.5) (D3) and 0.8 M lithium chloride/0.5 M Tris-HCl/8.5 M urea (pH 6.8) (D4). Adducts were located by autoradiography on X-ray film (Fuji Photo Film, Tokyo, Japan) with intensifying screens (Konica, Tokyo, Japan) for 24 h at -80°C. For quantitative estimation of adduct levels, located adducts were excised and counted by the Cerenkov counting assay using comparable background areas for control counts as described by Reddy and Randerath (18) . All experiments were performed two or three times, and the results obtained were reproducible.
Results

Cytotoxicity
Relative cell survivals following treatment of SHE cells with E 2 , E 1 or their catechol estrogens at 1-10 µg/ml for 6 h are shown in Figure 1 . Cell survivals were not decreased by treatment with E 2 at any concentration (Fig. 1A) . However, statistically significant decreases in cell survivals were elicited by treatment with 2-or 4-OHE 2 in a concentration-dependent manner ( Figure 1B and C). When 2-or 4-OHE 2 was administered to cells at 1 or 3 µg/ml, the cytotoxicities, as determined by cell survivals, were similar with the both catechol estrogens. However, 2-OHE 2 was more cytotoxic than 4-OHE 2 when administered at 10 µg/ml ( Figure 1B and C) . Similar results were observed in cells treated with E 1 or its catechol estrogens ( Figure 1D-F) .
DNA adduct formation
When SHE cells were treated for 6 h with 1 µg/ml B[a]P as a positive control, DNA from the cells exhibited a number of extra spots on the chromatogram not seen in the control cells (Figure 2A and B) . In contrast, DNA adducts were not detected in SHE cells treated with E 2 at 10 and 30 µg/ml for 6 h ( Figure 2C and D) . No detectable adducts were formed in DNA from cells treated with E 1 at 10 and 30 µg/ml for 6 h ( Figure 2E and F) . DNA adducts were not induced even in cells treated with either E 1 or E 2 at 10 µg/ml for 24 h (data not shown). Treatment with E 2 or E 1 at 30 µg/ml for 24 h was too toxic to analyze DNA adduct formation. On the other hand, SHE cells treated with 2-or 4-OHE 2 at 10 µg/ml for 6 h exhibited a single DNA adduct ( Figure 3A and B). The adduct spot produced by 2-OHE 2 was observed at a different location on the chromatogram from that produced by 4-OHE 2 . To clarify the difference in the location, DNA from SHE cells treated with 2-OHE 2 was analyzed by cochromatography with DNA from cells treated with 4-OHE 2 . As shown in Figure 3C , the DNA adduct produced by 2-OHE 2 (spot a) migrated faster than that induced by 4-OHE 2 (spot b), indicating that both adducts can be resolved separately in co-chromatography experiments.
When cells were treated with 2-or 4-OHE 1 at 10 µg/ml for 6 h, one major and one minor adduct were detected on the chromatograms (Figure 4) . The levels of adducts produced by 4-OHE 1 were greater than those induced by 2-OHE 1 . There were, however, no differences in the location of the two adduct spots between the cells treated with either 2-or 4-OHE 1 . These results were confirmed by co-chromatography with the mixture of DNAs from both cells treated with 2-or 4-OHE 1 (data not shown).
We next examined the treatment time and concentration dependencies of DNA adduct formation. When cells were treated with 10 µg/ml 4-OHE, for 1, 3 or 6 h, two adduct spots were detected as described above. Quantitative estimation by Cerenkov counting was performed to compare the levels of DNA adducts. The total number of two DNA adducts formed in the 1, 3 or 6 h-treatment group was estimated to be 1.89, 3.81 or 4.00 adducts in 10 8 nucleotides, respectively. Treatment of cells with 4-OHE 1 at 0.3-10 µg/ml for 6 h induced DNA adducts in a concentration-dependent manner as shown in Figure 5 . The same results were obtained with 2-OHE 1 . Although DNA adducts were not detected in cells treated with 2-OHE 1 at 0.3 or 1 µg/ml for 6 h, treatment of cells with 2-OHE 1 at 3 or 10 µg/ml elicited DNA adducts in a concentration-dependent manner. To compare the ability of estrogens to induce DNA adducts in SHE cells, the levels of DNA adducts induced were quantitatively estimated by Cerenkov counting (Table I) . When compared, the total number of DNA adducts in 10 8 nucleotides in cells treated with various estrogens at 10 µg/ml for 6 h, the capability of inducing DNA adducts was ranked as follows:
Effect of L-ascorbic acid on the levels of catechol estrogeninduced DNA adducts
When SHE cells were treated with 0.25 mM L-ascorbic acid for 6 h, no DNA adducts were detected as compared with the control cells ( Figure 6B ). DNA adducts induced by treatment of cells with 10 µg/ml 2-OHE 2 for 6 h were markedly decreased by co-treatment with 0.25 mM L-ascorbic acid ( Figure 6C and D) . The co-treatment with 2-OHE 2 and Lascorbic acid decreased the level of DNA adducts by 23% compared with that of adducts induced by 2-OHE 2 alone. A slight level of DNA adducts was observed even when cells were co-treated with 2.5 mM L-ascorbic acid (data not shown). The same results were observed in cells treated with 10 µg/ ml 4-OHE 2 in the presence of 0.25 mM L-ascorbic acid ( Figure 6E and F) . Co-treatment of cells with L-ascorbic acid also profoundly decreased DNA adducts induced by 2-or 4-OHE 1 at 10 µg/ml for 6 h (data not shown).
Discussion
In the present study, we examined the abilities of E 2 , E 1 and four of their catechol metabolites to induce DNA adducts in (17) treated for 48 h at the concentrations that induced DNA adducts are ranked in the same order as the DNA adductinducing abilities. In addition, the adduct-inducing abilities correspond with the abilities of these catechol estrogens to induce chromosome aberrations and gene mutations at the Na ϩ /K ϩ ATPase and/or hprt loci in SHE cells (17) . These results indicate that genetic damage as detected by 32 Ppost-labeling can act as the initiator in estrogen-induced carcinogenesis. However, it is not clear whether the difference in the abilities to induce the genetic effects among the catechol estrogens is attributed to the difference in the intrinsic feature or the metabolic fate of the chemicals. In the hamster kidney tumor model, 4-hydroxy catechol estrogens are carcinogenic, whereas 2-hydroxy catechol estrogens are not (7, 8) . Liehr and his collaborators demonstrated that hamster kidney contains high estrogen 4-hydroxylase activity (19) and that the methylation of 4-OHE 2 by catechol-O-methyltransferase is inhibited by 2-OHE 2 in vitro (20) . This may facilitate accumulation of 4-OHE 2 in the hamster kidney. However, the lack of carcinogenic activity of 2-OHE 2 in the hamster model can also be due to rapid methylation and rapid metabolic clearance of 2-OHE 2 itself (21). Cavalieri et al. (11) showed that 2-or 4-hydroxy catechol estrogens of E 2 and E 1 are oxidized to E 2 (E 1 )-2,3-or 3,4-quinones and form DNA adducts in vitro and in vivo. Recently, Newbold and Liehr (9) have demonstrated that although the incidence is lower than that of 4-OHE 2 , 2-OHE 2 also induces uterine adenocarcinoma in mice. In addition, our previous results showed that direct treatment of SHE cells with 2-hydroxy catechol estrogens (2-OHE 2 and 2-OHE 1 ) induces morphological transformation, chromosome aberrations and aneuploidy in the cells (17) . These findings suggest an intrinsic carcinogenic and mutagenic activity of 2-hydroxy catechol estrogens. The molecular characteristic of DNA adducts induced by 2-or 4-OHE 2 (E 1 ) in SHE cells is unknown. The depurinating adduct 4-OHE 2 (E 1 )-1(α,β)-N7 guanine is formed in vitro by reaction of E 2 (E 1 )-3,4-quinones with DNA or by activation of 4-OHE 2 (E 1 ) with horseradish peroxidase, lactoperoxidase or cytochrome P450 in the presence of DNA (11) . The same depurinating adduct is detected in rat mammary glands following exposure by intramammillary injection of 4-OHE 2 or E 2 -3,4-quinone (11) . When E 1 -2,3-quinone is reacted with deoxyguanosine or deoxyadenosine in vitro, 2-OHE 1 -6-N 2 deoxyguanosine or 2-OHE 1 -6-N 6 deoxyadenosine is formed, respectively (10) . In SHE cells, a single DNA adduct was formed by 2-or 4-OHE 2 , whereas one major and one minor adduct were produced by 2-or 4-OHE 1 . Studies on the molecular characterization of the adducts formed in SHE cells are currently in progress.
The levels of DNA adducts induced by 4-OHE 2 (E 1 ) are higher than those by 2-OHE 2 (E 1 ). The differential levels of DNA adducts induced by 2-and 4-OHE 2 (E 1 ) may come from dissociation of 2-OHE 2 (E 1 )-induced adducts from DNA because of high sensitivity to enzyme digestion during a 32 Ppost-labeling assay. This is, however, unlikely because the DNA adduct-inducing abilities of both catechol estrogens correlate well with the abilities of these estrogens to induce cellular transformation, chromosome aberrations and gene mutations in SHE cells as described above.
Although E 2 and E 1 are carcinogenic, they failed to induce DNA adducts in SHE cells. Administration by implantation of E 2 for up to 9 months induces renal carcinoma in 100% of male Syrian hamsters (14) . DNA adducts are detected in the kidney. The adduct levels are maximum at 5 months after initial E 2 implantation but weak at 1 month (22) , indicating that DNA adduction by E 2 becomes manifest only after prolonged chronic exposure of animals to the estrogen. In SHE cells, E 2 induces morphological transformation, but fails to induce any detectable gene mutations or chromosome aberrations over the concentration range that induces cellular transformation (17) . The failure of E 2 to induce gene mutations and chromosome aberrations is consistent with the lack of DNA adduct-inducing ability of E 2 , which suggests that SHE cells do not retain some metabolizing enzymes or that the exposure times are too short to induce the changes seen in vivo. E 2 induces a specific type of genetic change, i.e. aneuploidy (17) . Because aneuploidy and cellular transformation in SHE cells are mechanistically related (4), the ability of E 2 to induce aneuploidy could participate in SHE cell transformation by E 2 . As far as we know, there is no report on the induction of DNA adducts by E 1 . E 1 induces cellular transformation, chromosome aberrations and aneuploidy in SHE cells. However, gene mutations are not elicited in SHE cells by E 1 (17) . No mutagenic activity of E 1 in Chinese hamster V79 cells is also noted by Drevon et al. (23) . Clastogenic and/or aneugenic activities could play a role in the carcinogenic activity of E 1 .
Epidemiological studies have shown that L-ascorbic acid intake has the statistically significant inverse association with breast cancer risk (24) . Additionally, L-ascorbic acid is not carcinogenic to rats or mice given 5% with diet for 2 years (25) . Co-administration of L-ascorbic acid to E 2 -or DEStreated male Syrian hamsters reduces the incidence of renal carcinoma by~50% (26) . Concomitant administration of Lascorbic acid and DES decreases the levels of DNA adducts by 70% in the kidney of hamsters and the in vitro concentrations of DES-4',4Љ-quinone, which is the reactive metabolic intermediate of DES (27) . The inhibitory effect of L-ascorbic acid on hormonal carcinogenesis and DNA adduct formation may be a result of preventing oxidation of catechol estrogens or DES to their respective quinones and/or scavenging free radicals. In the present study, L-ascorbic acid decreased DNA adduct levels induced by 2-or 4-OHE 2 (E 1 ) in SHE cells, indicating that oxidative intermediates of the catechol estrogens may contribute to DNA adduct formation in SHE cells. However, it is not clear whether oxidative products of the catechol estrogens bind to DNA directly, or whether free radicals generated by redox cycling between the catechol estrogens and the quinone intermediates participate in the adduct formation.
No growth-stimulating activities are observed in SHE cells treated with any of the estrogens examined in the present study (17) , which is consistent with the findings that SHE cells do not express measurable levels of estrogen receptor (4). Newbold and Liehr (9) compared estrogenic potency and carcinogenic activity of catechol estrogens in neonatal mouse uteri. 2-OHE 2 was less estrogenic but more carcinogenic than E 2 . The estrogenic activity of 4-OHE 2 was 60% higher but its carcinogenic activity was 9-fold higher than E 2 . Their findings indicate that the estrogenicity is not sufficient to explain the carcinogenic activity of these catechol estrogens, and the involvement of genetic alterations in the catechol estrogeninduced carcinogenesis is also suggested.
In summary, we have demonstrated that catechol metabolites of E 2 and E 1 induce DNA adducts in SHE cells, but neither E 2 nor E 1 are active in inducing DNA adducts. The ability to induce DNA adducts correlated well with the transforming ability of these estrogens described previously (17) . The levels of DNA adducts induced by the catechol estrogens were decreased by co-treatment of cells with L-ascorbic acid. The data indicate the involvement of oxidative metabolites of catechol estrogens of E 2 and E 1 in the initiation of endogenous estrogen-induced carcinogenesis.
